Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK® ...

Vertex Pharmaceuticals (VRTX) on Tuesday announced that the European Commission has granted approval for Alyftrek for the ...

Vertex Pharmaceuticals today announced that the European Commission has granted approval for Alyftrek ...

VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to ...

ALYFTREK and TRIKAFTA are not recommended in patients with moderate hepatic impairment and should only be considered when there is a clear medical need and benefit outweighs risk.

Alyftrek and Journavx — The Two Big Launches. According to JPMorgan analyst Jessica Fye, investors will be laser-focused on the company’s two big launches: Alyftrek and Journavx.

Alyftrek, which was approved in December 2024, has a US list price of $370,000 per year. We estimate that Kalydeco, Orkambi, and Symdeko all command pricing upward of $230,000-$250,0000 a year for ...

ALYFTREK should only be considered when there is a clear medical need and benefit outweighs risk. If ALYFTREK is used, monitor patients closely. If TRIKAFTA is used, use with caution at a reduced ...

ALYFTREK should only be considered when there is a clear medical need and benefit outweighs risk. If ALYFTREK is used, monitor patients closely. If TRIKAFTA is used, use with caution at a reduced ...

ALYFTREK. There are no available safety data for ALYFTREK in patients who previously discontinued or interrupted treatment with drugs containing ELX, TEZ, or IVA due to adverse reactions.

ALYFTREK should only be considered when there is a clear medical need and benefit outweighs risk. If ALYFTREK is used, monitor patients closely. If TRIKAFTA is used, use with caution at a reduced ...